Eleven Biotherapeutics (NASDAQ:EBIO) was up 13.7% during trading on Monday . The stock traded as high as $1.58 and last traded at $1.58. Approximately 2,405,692 shares were traded during mid-day trading, an increase of 62% from the average daily volume of 1,484,665 shares. The stock had previously closed at $1.39.
Several equities research analysts have commented on EBIO shares. HC Wainwright set a $2.00 price target on shares of Eleven Biotherapeutics and gave the company a “buy” rating in a report on Thursday. ValuEngine raised shares of Eleven Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
The firm has a market cap of $59.92, a P/E ratio of -1.42 and a beta of 2.97.
A hedge fund recently raised its stake in Eleven Biotherapeutics stock. Vanguard Group Inc. grew its position in Eleven Biotherapeutics (NASDAQ:EBIO) by 17.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 206,450 shares of the biopharmaceutical company’s stock after acquiring an additional 30,600 shares during the period. Vanguard Group Inc. owned about 1.34% of Eleven Biotherapeutics worth $324,000 at the end of the most recent quarter. 15.43% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/16/eleven-biotherapeutics-ebio-trading-up-13-7.html.
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc, a biologic oncology company, focuses on the design and development of targeted protein therapeutics (TPTs). It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. The company's lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck.
Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.